GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sonic Healthcare Ltd (FRA:SAB) » Definitions » Valuation Rank

Sonic Healthcare (FRA:SAB) Valuation Rank


View and export this data going back to . Start your Free Trial

What is Sonic Healthcare Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Sonic Healthcare Valuation Rank Related Terms

Thank you for viewing the detailed overview of Sonic Healthcare's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonic Healthcare Business Description

Traded in Other Exchanges
Address
225 George Street, Level 22, Grosvenor Place, Sydney, NSW, AUS, 2000
Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 40% of group revenue in Australia and New Zealand, 25% in the US, and 35% in Europe.